Clinical Trial

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 25, 2024 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of cadonilimab (AK104) in combination with anlotinib in the treatment of locally advanced or metastatic melanoma.
Trial Details
NCT Number NCT06327698
Lead Sponsor Hunan Cancer Hospital
Conditions Melanoma
Enrollment 30 participants
Start Date 2024-05-15
Primary Completion 2026-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2024-03-25